skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Ublituximab (Code C91078)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Ublituximab

Definition: A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ublituximab specifically binds to the B cell-specific cell surface antigen CD20, thereby potentially inducing a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies. Ublituximab has a specific glycosylation profile, with a low fucose content, that may enhance its ADCC response against malignant B cells.

Display Name: Ublituximab

Label: Ublituximab

NCI Thesaurus Code: C91078 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2934225  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
LFB-R603
TG-1101
TG-20
TGTX-1101
Ublituximab

External Source Codes: 
PDQ Closed Trial Search ID 670500
PDQ Open Trial Search ID 670500 (check for NCI PDQ open clinical trial info)
UMLS CUI C2934225

Other Properties:
     Name Value (qualifiers indented underneath)
code C91078
Contributing_Source CTRP
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91078

Mainbox Bottom